Abstract: Background: A definitive treatment of SARS CoV-2 is yet to arrive and the human death toll rises exponentially globally. In this health emergency, it might be useful to look into the old therapies which could be effective against the virus. In vitro research showed Ivermectin could decrease the concentration of coronavirus 4000 to 5000 folds in living lung tissue. Aim: In this prospective study a combination of Ivermectin and Doxycycline will be evaluated therapeutically to treat COVID-19 patients. Methods: 100 COVID-19 patients were enrolled in this study with a predefined inclusion and exclusion criteria. RT- PCR of the SERS-CoV-2 will be done at designated government hospitals. The clinical features and response to treatment were noted according to a dedicated protocol. Results: In this study male and female were 64 and 36 respectively, the age ranged between 8 to 84 years. Retesting was done between 4 and 18 days of starting medication. All patients tested negative and their symptoms improved within 72 hours. There were no noticeable side effects. Conclusion: Combination of Ivermectin and doxycycline was found to be very effective in viral clearance in mild and moderately sick COVID-19 patients. Medical societies and institutions should undertake larger multi center studies to validate and recommend this combination therapy to include in national guidelines. Keywords: Covid-19, Doxycycline, Ivermectin Bangladesh Coll Phys Surg 2020; 38: 10-15) DOI: https://doi.org/10.3329/jbcps.v38i0.47512 a. Prof. Mohammed Tarek Alam, Professor and Head of Department of Medicine, Bangladesh Medical College, House # 34, Road # 14/A, R/A, Dhaka-1209, Bangladesh b. Rubaiul Murshed, Chairperson, Shomman Foundation, House # 71/1, Road # 15/A, Dhanmondi R/A, Dhaka-1209, Bangladesh & Chief Consultant, Central Police Hospital, 2 DIT Ave, Dhaka 1000, Bangladesh c. Dr. Elias Bhiuyan, Assistant Professor, Department of Medicine Bangladesh Medical College, House # 34, Road # 14/A, R/A, Dhaka-1209, Bangladesh d. Dr. Sadia Saber, Medical Officer, Department of Medicine Bangladesh Medical College, House # 34, Road # 14/A, R/ A, Dhaka-1209, Bangladesh e. Rafa Faaria Alam , Faculty Member, School of Public Health and Life Science, University of South Asia, Dhaka-1212, Bangladesh f. Rishad Choudhury Robin, Associate Project Lead, Shomman Foundation, House # 71/1, Road # 15/A, Dhanmondi R/A, Dhaka-1209, Bangladesh Address of Correspondence: Dr. Mohammed Tarek Alam, Professor and Head of Department of Medicine, Bangladesh Medical College, House # 34, Road # 14/A, R/A, Dhaka-1209, Bangladesh. E-mail: mtarekalam16@gmail.com, Phone: +8801819-185449 A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline MT ALAM a , R MURSHED b , E BHIUYAN c , S SABER d , RF ALAM e , RC ROBIN f Background: One hundred years after the Spanish flu pandemic in 1918-20, the whole world is again facing devastation due to the Covid-19 (SARS CoV-2) pandemic. This virulent virus SARS CoV-2 has high infectivity, morbidity and remarkable fatality rate. No specific treatment or vaccine has been invented to save mankind yet. Scientists, physicians and concerned multidisciplinary professional including political leaders are united to explore a quick effective treatment and vaccine before it is too late. Empirical applications of some drugs have been assumed to work with success, but without having a clinical trial, they cannot be validated. Until anything comes up, it might be useful to repurpose old therapies which could be effective against the virus. In the beginning of April 2020, Caly et al. from Monash University, Australia published their research article stating that a single dose of Ivermectin (an anti- parasitic drug) could decrease the concentration of coronavirus in vitro. In the lab, Caly et al. bathed Vero- hSLAM cells with Ivermectin at a concentration of 5M from 2 hours post-infection SARS-CoV-2 isolate Australia/VIC01/2020 until the conclusion of the experiment. SARS-CoV-2 RNA was determined by RT- PCR at days 0-3 in both supernatant and cell pellet experiments. The authors noted 93-99.8% reduction in viral RNA for Ivermection versus DMSO control at 24h in the supernatant (released virions) and cell associated viral RNA (total virus) respectively. They also describe by 48 hours about 5000 fold reduction of viral RNA and maintenance of effect at 72 hours. 1 They concluded that the human dose needed to be ascertained in further studies. In the current SARS-CoV- 2 pandemic, this news was a ray of hope. Journal of Bangladesh College of Physicians and Surgeons Vol. 38, COVID-19 (Supplement Issue), July 2020